Royalty Pharma Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -1.09%165.320.7%$1060.19m
PFEPfizer Inc. 3.69%50.070.9%$942.34m
ABBVAbbVie, Inc. 0.35%142.571.9%$843.43m
MRKMerck & Co., Inc. 2.33%91.010.7%$812.67m
LLYEli Lilly & Co. 2.53%307.781.1%$790.95m
BMYBristol-Myers Squibb Co. 1.48%75.561.0%$658.77m
SIGASIGA Technologies, Inc. -0.16%24.750.0%$468.87m
AZNAstraZeneca Plc 3.08%66.641.0%$384.79m
GBTGlobal Blood Therapeutics, Inc. 0.27%66.755.6%$307.02m
ALNYAlnylam Pharmaceuticals, Inc. 1.94%233.858.2%$285.78m
GSKGSK Plc 0.84%36.030.3%$273.25m
HZNPHorizon Therapeutics Plc 0.55%67.475.4%$217.29m
KRTXKaruna Therapeutics, Inc. 6.17%277.420.0%$207.23m
CCXIChemoCentryx, Inc. 0.24%50.722.9%$191.50m
NVONovo Nordisk A/S -0.67%107.480.1%$184.93m

Company Profile

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.